MICHAEL A DAVIES to Drug Resistance, Neoplasm
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Drug Resistance, Neoplasm.
Connection Strength
0.846
-
Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol. 2014 Feb 01; 87(3):381-9.
Score: 0.178
-
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012 Jan; 35(1):66-72.
Score: 0.156
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.060
-
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
Score: 0.060
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.056
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.053
-
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47.
Score: 0.047
-
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014 Sep 01; 74(17):4845-4852.
Score: 0.046
-
Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):523-36.
Score: 0.046
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67.
Score: 0.042
-
The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012 Mar-Apr; 18(2):142-7.
Score: 0.039
-
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
Score: 0.018
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.013
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.013
-
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 2014 Mar; 124(3):1406-17.
Score: 0.011
-
In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res. 2011 Apr; 24(2):386-9.
Score: 0.009